التفاصيل البيبلوغرافية
| العنوان: |
Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy. |
| المؤلفون: |
Panicucci, Chiara, Sahin, Eray, Bartolucci, Martina, Casalini, Sara, Brolatti, Noemi, Pedemonte, Marina, Baratto, Serena, Pintus, Sara, Principi, Elisa, D'Amico, Adele, Pane, Marika, Sframeli, Marina, Messina, Sonia, Albamonte, Emilio, Sansone, Valeria A., Mercuri, Eugenio, Bertini, Enrico, Sezerman, Ugur, Petretto, Andrea, Bruno, Claudio |
| المصدر: |
Cellular & Molecular Life Sciences; 9/10/2024, Vol. 81 Issue 1, p1-15, 15p |
| مصطلحات موضوعية: |
LIQUID chromatography-mass spectrometry, SPINAL muscular atrophy, MACHINE learning, CEREBROSPINAL fluid examination, PROTEIN expression, COMPLEMENT activation |
| مستخلص: |
Aim: The availability of disease-modifying therapies and newborn screening programs for spinal muscular atrophy (SMA) has generated an urgent need for reliable prognostic biomarkers to classify patients according to disease severity. We aim to identify cerebrospinal fluid (CSF) prognostic protein biomarkers in CSF samples of SMA patients collected at baseline (T0), and to describe proteomic profile changes and biological pathways influenced by nusinersen before the sixth nusinersen infusion (T302). Methods: In this multicenter retrospective longitudinal study, we employed an untargeted liquid chromatography mass spectrometry (LC-MS)-based proteomic approach on CSF samples collected from 61 SMA patients treated with nusinersen (SMA1 n=19, SMA2 n=19, SMA3 n=23) at T0 at T302. The Random Forest (RF) machine learning algorithm and pathway enrichment analysis were applied for analysis. Results: The RF algorithm, applied to the protein expression profile of naïve patients, revealed several proteins that could classify the different types of SMA according to their differential abundance at T0. Analysis of changes in proteomic profiles identified a total of 147 differentially expressed proteins after nusinersen treatment in SMA1, 135 in SMA2, and 289 in SMA3. Overall, nusinersen-induced changes on proteomic profile were consistent with i) common effects observed in allSMA types (i.e. regulation of axonogenesis), and ii) disease severity-specific changes, namely regulation of glucose metabolism in SMA1, of coagulation processes in SMA2, and of complement cascade in SMA3. Conclusions: This untargeted LC-MS proteomic profiling in the CSF of SMA patients revealed differences in protein expression in naïve patients and showed nusinersen-related modulation in several biological processes after 10 months of treatment. Further confirmatory studies are needed to validate these results in larger number of patients and over abroader timeframe. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cellular & Molecular Life Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Find this article in full text from Springer Verlag. 
Full Text Finder